lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Ipsen Pharma
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
April 23, 2026
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
April 22, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
March 27, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
March 18, 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
March 12, 2026